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Cryoprecipitate is frequently administered as treatment for hemostatic defects in patients with
uremia. The only published data supporting this approach however, involves seven patients
described by Janson and colleagues in whom bleeding times were shortened and bleeding
complications reduced after cryoprecipitate infusion. We retrospectively reviewed our institu-
tion's experience with cryoprecipitate in this setting. Five patients had sufficiently complete data
for evaluation of the efficacy of therapy with cryoprecipitate, including pretreatment bleeding
time > 15 minutes, normal coagulation studies, and platelet count > 100,000/isl. Two patients
had normalization of their bleeding time and a favorable clinical outcome after cryoprecipitate
infusion. Three patients failed to shorten their bleeding time after cryoprecipitate infusion or, in
one case, multiple infusions. One ofthese latter patients had correction ofhis abnormal bleeding
time after subsequent administration of deamino-8-D-arginine vasopressin (DDAVP). We
conclude that the hemostatic response tocryoprecipitate therapy isvariable, and that cryoprecip-
itate therapy does not achieve restoration of normal hemostasis in some patients with uremic
bleeding.
INTRODUCTION
Bleeding and hemostatic defects are common complications of uremia. Multiple
abnormalities in laboratory tests of hemostasis have been reported [2-4]. These
abnormalities include defects in platelet aggregation, platelet retention, platelet factor
3 availability, and prostaglandin synthesis. These defects may contribute to the
frequently observed prolongations of the bleeding time found in uremic patients [5].
The exact mechanism underlying these abnormalities remains obscure. Not surpris-
ingly, therapy is also problematic in many cases. Dialysis has been the standard
therapy for uremic bleeding, although at times it is ineffective [6,7]. Recently,
cryoprecipitate and deamino-8-D-arginine vasopressin (DDAVP) have emerged as
therapeutic alternatives [1,8-10].
While cryoprecipitate is widely used for hemostatic alterations or bleeding second-
ary to renal failure, very little data exist to support this approach. Janson and
associates reported seven patients in whom the bleeding time shortened and bleeding
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complications were reduced after cryoprecipitate therapy [1]. To our knowledge, there
have been only two other case reports on the use of cryoprecipitate in uremia [11,12].
While many hematologists believe that cryoprecipitate works only in some uremic
patients, there are no reported data contradicting the initial uniformly positive
findings. We performed a retrospective review of uremic patients who received
cryoprecipitate therapy in our institution in order to determine whether laboratory
abnormalities or bleeding were consistently ameliorated by this therapy, as suggested
in the original report.
MATERIALS AND METHODS
Patients
The medical records of 82 consecutive patients discharged from Strong Memorial
Hospital, Rochester, New York, between April 1984 and January 1987 with a
diagnosis ofrenal failure (acute or chronic), who had received cryoprecipitate therapy
were reviewed. For unambiguous evaluation of efficacy from the standpoint of this
study, we felt that the following information or situtations were required: (1) platelet
count > 100,000/,ul so that patients whose bleeding time abnormality or bleeding
might be on the basis of thrombocytopenia would not be included, (2) normal
prothrombin time (PT) and/or activated partial thromboplastin time (PTT) so that
patients whose bleeding was on the basis of deficiencies of coagulation factors
measured in these assays would not be included, and (3) prolonged template bleeding
time with at least one post-infusion bleeding time. Five of 82 patients met all these
criteria (four males and one female). Many of the patients were not evaluable simply
because no post-infusion bleeding time had been performed.
All five patients had an elevated template bleeding time > 15 minutes (normal, four
to nine minutes) prior to therapy, and an elevated blood urea nitrogen (BUN) ranging
from 41 to 99 mg/dl. None had taken platelet function-altering drugs. Three patients
(patients 2, 3, and 5) were dialyzed within 24 hours prior to their cryoprecipitate
infusions, and two patients received additional pre-infusion blood transfusions (patient
3 received fresh frozen plasma; patient 4 received red blood cells). The abnormal
bleeding times were measured after administration of these components. None re-
ceived platelet transfusions. Table 1 summarizes the clinical and laboratory data for
the five patients immediately prior to cryoprecipitate therapy.
Laboratory
Platelet counts were done on a Coulter Counter S-Plus STKR or S Plus Jr. (Coulter
Electronics Inc., Hialeah, FL). Prothrombin timeand activated partial thromboplastin
time employed an automated Simplastin reagent and automated methods (General
Diagnostics, Durham, NC), respectively. Bleeding times were performed by inflating
an arm blood pressure cuffto 40 mm Hg and making a vertical forearm incision with a
Simplate II (General Diagnostics) kit. Blotting with filter paper was performed every
30 seconds. The normal range in our hospital for this method is four to nine minutes.
Bleeding times extending past 15 minutes are shown as > 15 minutes. Cryoprecipitate
was obtained from the Strong Memorial Blood Bank as prepared by the American Red
Cross Services, Rochester Region, Rochester, New York, by accepted methods [13].
Our standard dose of cryoprecipitate for a uremic adult patient is 10 units infused
intravenously over approximately 30 minutes.
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TABLE 1
Clinical Information
Patient Patient Patient Patient Patient
1 (CW) 2 (JK) 3 (VW) 4 (FG) 5 (SM)
Age/Sex 24/Female 23/Male 32/Male 20/Male 21/Male
Diagnosis Medullary Reflux Toxic shock Lupus Reflux
cystic disease hydronephrosis syndrome nephritis hydronephrosis
BUN 59 41 99 48 49
Creatinine 5.2 13.5 10.2 7.7 14.1
Platelet count 207,000 223,000 258,000 204,000 104,000
Hematocrit 25 23 27 27 21
PT/PTT 12.9 12.9 11.1 10.8 12.7
25.5 28.5 31 27.1
History ofbleeding Easy bruising Hemoptysis None None None
bleeding gums
and teeth
Normal ranges: BUN, 8-22 mg/dl; Creatinine, 0.5-1.0 mg/dl; PTT, 25.0-37.0 sec; PT,9.5-12.5 sec
RESULTS
The effects ofcryoprecipitate therapy on bleeding time and clinical outcome for the
five patients are summarized in Table 2.
Patients Who RespondedSatisfactorily to Cryoprecipitate Therapy
Two patients (patients 1 and 3) achieved normal bleeding times aftercryoprecipitate
infusion. In the bleeding patient (patient 3), this laboratory improvement was accom-
panied by cessation of bleeding from a subclavian vein dialysis catheter site. This
bleeding gradually subsided over a four-day period, during which cryoprecipitate
therapy (10 U daily or 0.95 U/10 kg) had failed to correct the bleeding time initially,
improved to 12.0 minutes after the third dose, and normalized 16 hours after the last
dose (fourth day) ofcryoprecipitate therapy.
The asymptomatic patient (patient 1) received two preoperative cryoprecipitate
doses that weresix hours apart and consisted of 10 U (1.6 U/I0 kg) each. The bleeding
time corrected to 8.5 minutes, five hours after the second dose. Open renal biopsy was
performed without complications. An additional similar dose of cryoprecipitate was
given during the procedure. Repeat bleeding time seven hours after this last dose had
returned to > 15 minutes.
Patients with No Evidence ofResponse to Cryoprecipitate Therapy
Two patients (patients 2 and 5) were given cryoprecipitate, but the bleeding time
remained abnormal. Patient 2 had been admitted for bilateral nephrectomy required
for reflux hydronephrosis. The initial bleeding time was > 15 minutes. Ten units of
cryoprecipitate (1.4 U/10 kg) were infused, with one hour and seven hours post-
infusion bleeding times remaining > 15 minutes. Two additional similar doses of
cryoprecipitate were given five hours apart, and repeat bleeding time five hours after
the last dose was still > 15 minutes. A fourth dose (1.4U/I0 kg) ofcryoprecipitate was
given on the day ofsurgery, with a two-hour post-infusion bleeding time > 15 minutes.
The patient was vigorously dialyzed and started on estrogen therapy (20 mg premarin
intravenously) on the day prior to surgery. Despite a persistently elevated bleeding
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TABLE 2
Results of Cryoprecipitate (Cryo) Infusion
Patient Patient Patient Patient Patient
1 2 3 4 5
BT before >15 minutes >15 minutes >15 minutes >15 minutes >15 minutes
infusion
BT after infusion 8.5 minutes >15 minutes 8 minutes 8 minutes >15 minutes
Post-infusion 5 hours 1 hour 16 hoursb 2 daysa 3 hours
BT interval and 7 hours
Procedure Open renal Bilateral Subclavian Renal biopsy Cadaveric
biopsy nephrectomy vein prior to renal
catheter therapy transplant
placement
Bleeding None None Oozing from Gross Perirenal and
complications catheter hematuria scrotal
prior to cryo hematoma
Outcome Continued Continued Bleeding No improvement No improvement
free of free of decreased after cryo; after cryo
complications complications after cryo decreased
with DDAVP
therapy
aPost-infusion BT was obtained two days after the last cryodose while two doses of DDAVP were given in
that interval. The BTofeight minutes likely reflected the DDAVP, not the cryo.
bThere was a gradual diminution ofBT after several cryodoses given over a 36-hour period with the BT of
eight minutes obtained 16 hours after the last dose. No other BT was performed in the 36-hour interval.
time, the patient underwent bilateral nephrectomy with satisfactory intraoperative
hemostasis. Premarin and 10 units of cryoprecipitate (1.4 U/10 kg) were given every
12 hours postoperatively, and no complications developed. No further bleeding times
were performed.
Patient 5 had been admitted for a cadaveric renal transplant and had a preoperative
bleeding time of > 15 minutes. No specific therapy was given for this hemostatic
abnormality. Postoperatively, perirenal and scrotal hematomas developed. Three days
postoperatively, 10 units of cryoprecipitate (1.8 U/10 kg) were given, and at three
hours post-infusion the bleeding time remained > 15 minutes. The patient continued to
have bleeding at the incision and required a transfusion of two units of red blood cells
for anemia.
Patient 4, after failing to respond to cryoprecipitate, had a correction of bleeding
time after DDAVP treatment. This patient had undergone a renal biopsy and
developed gross hematuria. A bleeding time done postoperatively was > 15 minutes.
Ten units of cryoprecipitate (1.1 U/10 kg) were infused with continued severe
hematuria over the next 16 hours, requiring 2 units of red blood cells for anemia. No
bleeding time was performed at this point. The lackofclinical improvement in bleeding
prompted a trial of DDAVP (27 mg intravenously). This first dose was given
approximately one day after the cryoprecipitate infusion. The patient improved, with
decrease in hematuria noted within one hour after DDAVP. A second dose ofDDAVP
was given 24 hours later, resulting in yet further decrease in hematuria. A bleeding
time done 13 hours after this dose of DDAVP was eight minutes. This check of
bleeding time was performed approximately two days after the cryoprecipitate ther-
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apy. Figure 1 displays the clinical course of this patient in terms of therapy and
response.
DISCUSSION
Janson and colleagues reported seven patients, all ofwhom had improvement in their
bleeding time by four hours after cryoprecipitate treatment [1]. The nadir value of
bleeding time occurred one to 12 hours after infusion. Consonant with the anecdotal,
contrary experience of many, only one of our five patients responded in a comparable
fashion (patient 1). One other patient had a beneficial effect ofcryoprecipitate therapy
(patient 3). This recipient showed a gradual decrease in bleeding time over 36 hours
with multiple doses of cryoprecipitate. A normal bleeding time of eight minutes was
finally obtained 16 hours after the fourth and last cryoprecipitate dose. Concomitantly
there was a gradual decrease in bleeding from a subclavian vein catheter site. These
data support the clinical usefulness ofcryoprecipitate, although with a different time
course of correction than that previously reported, and with one patient requiring
several doses prior to improvement.
Three patients, similar to those previously reported, had no apparent response to
cryoprecipitate therapy. Cryoprecipitate did not correct thebleeding timeinpatients 2,
4, and 5, nor did it ameliorate bleeding complications in patients 4and 5. Patient 4 is of
special interest in that his severe hematuria from a renal biopsy was not reduced after a
single dose ofcryoprecipitate therapy but did improve after twodoses ofDDAVP, with
a bleeding time shortened to eight minutes. While no post-cryoprecipitate infusion
bleeding time was obtained before DDAVP was started, the normal bleeding time
occurred two days after the infusion of cryoprecipitate and therefore was most likely
due to DDAVP rather than to the cryoprecipitate. The efficacy of DDAVP in the
setting ofuremia has been described [8,9].
While our case reports are limited by lack of a standardized treatment protocol,
some conclusions are possible. Contrary to the original report of uniform success,
correction ofbleeding time within a few hours after a singledoseofcryoprecipitate was
the exception rather than the rule in these five patients. Some patients may respond
only after multiple doses of cryoprecipitate. For practical purposes, some patients do
not respond at all, when urgent clinical interventions are required. The time course of
correction ofbleeding time inpatients responding tocryoprecipitate therapy appears to
be much more variable than that seen in theoriginally reported seven patients. At least
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one and occasionally more post-infusion bleeding times are necessary in order to
identify these patients.
The apparent efficacy of DDAVP in patient 4, in whom cryoprecipitate was
ineffective, is interesting in that it suggests that the mechanisms of action of DDAVP
and cryoprecipitate may be different. In addition, patient 4 received multiple red cell
transfusions. Several investigators have found a negative correlation between bleeding
time and hematocrit in uremic patients [14,15]. Abnormal bleeding times have
improved, but not necessarily normalized with red cell transfusion [14,15] or erythro-
poietin therapy [16] in anemic patients with renal failure. The relative contribution of
red cell transfusion and DDAVP to the normalized bleeding time in this patient is
impossible to quantitate, but the rapid clinical response to DDAVP suggests that this
was the primary therapeutic agent. We, and most others, would favor useofDDAVP in
most patients as initial treatment, due to its lower risk and possibly more rapid onset of
action. The risks associated with cryoprecipitate include post-transfusion hepatitis,
HIV infection, allergic or, rarely, anaphylactic reactions, and serologic incompatibility
due to red cell isoagglutinins. Cryoprecipitate should be reserved for those failing to
respond to DDAVP, for whom DDAVP is contraindicated, and perhaps when massive
bleeding or emergent operative intervention is required.
Our review also demonstrates that cryoprecipitate is frequently used without
evaluation ofwhether it has decreased the patient's riskofbleeding (i.e., correcting the
bleeding time). This use may be a necessary approach in some urgent situations;
however, in many instances where cryoprecipitate was given to reduce the risk of
bleeding, it appeared that the procedure would bedone whether improvement occurred
or not. Having decided that a hemostatic defect constitutes sufficient danger to expose
the patient to the risks of homologous transfusion, it seems inconsistent not to
determine that the desired benefit has been accomplished. Our data do suggest that
cryoprecipitate use in uremic patients in our institution is probably providing no
hemostatic improvement in a substantial number of patients, and that failure to
measure the bleeding time post-transfusion leaves the physician unaware ofits lack of
efficacy.
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